Comparative Pharmacology
Head-to-head clinical analysis: FIBRICOR versus GEMFIBROZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FIBRICOR versus GEMFIBROZIL.
FIBRICOR vs GEMFIBROZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FIBRICOR (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase, and reduces production of apolipoprotein C-III (an inhibitor of lipoprotein lipase). This leads to decreased triglyceride and increased HDL cholesterol levels.
Gemfibrozil is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and clearance of triglycerides from plasma, and reduced hepatic VLDL secretion. It also increases HDL cholesterol.
FIBRICOR (fenofibric acid) is dosed as 45 mg or 135 mg orally once daily, with or without food. The typical adult dose is 135 mg daily. For mixed dyslipidemia, the recommended dose is 135 mg once daily; for severe hypertriglyceridemia, start with 45 to 135 mg once daily, titrating based on response.
Oral: 600 mg twice daily, 30 minutes before morning and evening meals.
None Documented
None Documented
Clinical Note
moderateGemfibrozil + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Gemfibrozil."
Clinical Note
moderateGemfibrozil + Cyclosporine
"Gemfibrozil may increase the nephrotoxic activities of Cyclosporine."
Clinical Note
moderateGemfibrozil + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Gemfibrozil."
Clinical Note
moderateGemfibrozil + Clotrimazole
Terminal elimination half-life is approximately 20 hours (range 19-26 hours) in healthy volunteers, with clinical context indicating that steady state is achieved within 1 week of dosing.
Terminal elimination half-life is 1.5 hours. In patients with renal impairment, half-life may be prolonged up to 7-8 hours.
Approximately 60-70% of the dose is excreted renally as unchanged drug or glucuronide conjugate, and about 20-25% is excreted fecally. Biliary excretion is minimal.
Primarily renal (approximately 70% as unchanged drug and glucuronide conjugate) with about 6% fecal elimination. Biliary excretion is minimal.
Category C
Category D/X
Fibrate
Fibrate
"The metabolism of Clotrimazole can be decreased when combined with Gemfibrozil."